Fresenius Medical touts Crit-Line hemodialysis fluid management studies

Fresenius Medical Care‘s (NYSE:FMS) renal therapies group today released results from four studies of its Crit-Line monitor that looked to explore the relation between relative blood volume monitoring (RBV-M) and patient outcomes.

Data from the studies were presented at the 2018 American Society of Nephrology’s Kidney Week Symposium in San Diego, Calif.

Results from two of the studies indicated that managing fluid with RBV-M resulted in reduced hospitalizations for patients new to hemodialysis, and provided a “positive return on investment,” according to a press release.

A retrospective database analysis of 1,068 incident hemodialysis patients indicated that there was a reduction of between 4.7 and 5.8 hospital days per year when RBV-M was used to manage fluid removal. The analysis examined data from incident patients at nine Renal Research Institute dialysis facilities between 2009 and 2017, Fresenius said.

In a separate economic model, RBV-M fluid management with Crit-Line was shown to reduce treatments and provide a positive return on investment within the first year, the company said.

“Active monitoring of relative blood volume can impact hospitalizations and missed treatments, helping fulfill our primary goal to improve the quality of life for patients with kidney failure. These new studies highlight the benefits of using a device like Crit-Line to improve dialysis treatments and lower overall healthcare costs,” renal therapies group prez Mark Costanzo said in a press release.

Earlier this month, Fresenius saw shares drop approximately 17% after it cut its outlook for the rest of the year on lower-than-expected third-quarter results.

The post Fresenius Medical touts Crit-Line hemodialysis fluid management studies appeared first on MassDevice.

from MassDevice https://ift.tt/2ENKxRr